Palvella Therapeutics Inc
PVLA59.040USD
+2.470+4.37%
收盘 09/18, 16:00（美东）报价延迟15分钟
652.96M总市值
亏损市盈率 TTM
关于 Palvella Therapeutics Inc 公司
Palvella Therapeutics, Inc.（前身为 Pieris Pharmaceuticals, Inc.）是一家临床阶段的生物制药公司。该公司专注于开发和商业化新型疗法，以治疗患有严重、罕见遗传性皮肤病的患者。该公司正在基于其专利的 QTORIN 平台开发一系列候选产品，最初专注于严重、罕见的遗传性皮肤病。其主要候选产品 QTORIN 3.9% 雷帕霉素无水凝胶（QTORIN 雷帕霉素）正在接受微囊性淋巴管畸形（微囊性 LM）的 III 期 SELVA 临床试验和皮肤静脉畸形的 II 期试验。该公司还致力于开发其他严重的、功能性衰弱性皮肤病的治疗方法，这些皮肤病是由哺乳动物雷帕霉素靶标 (mTOR) 通路过度激活引起的。
公司简介
公司代码PVLA
公司名称Palvella Therapeutics Inc
上市日期Dec 18, 2014
CEOMr. Wesley H. (Wes) Kaupinen
员工数量14
证券类型Ordinary Share
年结日Dec 18
公司地址125 Strafford Ave
城市WAYNE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编19087
电话14842531461
网址https://palvellatx.com/
公司代码PVLA
上市日期Dec 18, 2014
CEOMr. Wesley H. (Wes) Kaupinen
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey Martini, Ph.D.
Dr. Jeffrey Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
--
--
Dr. David W. Osborne, Ph.D.
Dr. David W. Osborne, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey Martini, Ph.D.
Dr. Jeffrey Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Kaupinen (Wesley H.)
14.53%
Frazier Life Sciences Management, L.P.
6.53%
Suvretta Capital Management, LLC
6.46%
BVF Partners L.P.
6.30%
Integrated Finance Group
5.06%
其他
61.11%
持股股东
持股股东
占比
Kaupinen (Wesley H.)
14.53%
Frazier Life Sciences Management, L.P.
6.53%
Suvretta Capital Management, LLC
6.46%
BVF Partners L.P.
6.30%
Integrated Finance Group
5.06%
其他
61.11%
股东类型
持股股东
占比
Hedge Fund
25.08%
Individual Investor
17.79%
Investment Advisor
9.58%
Private Equity
9.24%
Investment Advisor/Hedge Fund
6.33%
Other Insider Investor
5.06%
Venture Capital
3.23%
Research Firm
1.29%
Bank and Trust
0.07%
其他
22.33%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
113
8.02M
72.53%
+1.47M
2025Q1
119
7.23M
65.51%
+2.66M
2024Q4
118
6.14M
54.71%
+5.00M
2024Q3
118
806.99K
64.03%
-218.37K
2024Q2
120
474.51K
38.85%
-479.71K
2024Q1
135
564.53K
48.12%
-430.81K
2023Q4
149
574.40K
48.95%
-409.12K
2023Q3
161
703.90K
61.81%
-282.90K
2023Q2
173
831.24K
82.60%
-68.86K
2023Q1
202
592.51K
63.79%
-198.90K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Kaupinen (Wesley H.)
1.61M
14.54%
--
--
Apr 14, 2025
Frazier Life Sciences Management, L.P.
690.01K
6.24%
+36.12K
+5.52%
Mar 31, 2025
Suvretta Capital Management, LLC
714.46K
6.46%
--
--
Mar 31, 2025
BVF Partners L.P.
696.55K
6.3%
--
--
Mar 31, 2025
Integrated Finance Group
559.95K
5.06%
+559.95K
--
Apr 14, 2025
Woodline Partners LP
194.17K
1.76%
+194.17K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
110.75K
1%
+97.85K
+758.34%
Mar 31, 2025
Samsara BioCapital, LLC
679.49K
6.15%
--
--
Mar 31, 2025
Millennium Management LLC
269.84K
2.44%
+269.84K
--
Mar 31, 2025
Adams Street Partners, LLC
409.67K
3.71%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
ALPS Medical Breakthroughs ETF
0.24%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Growth ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
Global X Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
查看更多
ALPS Medical Breakthroughs ETF
占比0.24%
iShares Micro-Cap ETF
占比0.06%
iShares Russell 2000 Growth ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.02%
Global X Russell 2000 ETF
占比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
公告日期
类型
比率
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
